Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METATENSIN #4 vs ALDORIL D30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Reserpine depletes catecholamines from central and peripheral nerve terminals by inhibiting vesicular monoamine transporter (VMAT), reducing sympathetic outflow. Hydralazine directly relaxes arteriolar smooth muscle by increasing c GMP levels. Hydrochlorothiazide inhibits sodium-chloride symporter in distal convoluted tubule, reducing plasma volume.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
Hypertension
Hypertension
2 tablets sublingually every 4 hours as needed for angina. Each tablet contains nitroglycerin 0.6 mg.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
12-18 hours; prolonged to 24-36 hours in severe renal impairment (Cr Cl <30 m L/min)
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Reserpine: extensively metabolized in liver via unidentified pathways; Hydralazine: N-acetylation (polymorphic NAT2), also hydroxylation and glucuronidation; Hydrochlorothiazide: not significantly metabolized, excreted unchanged in urine.
Methyldopa is metabolized by conjugation (catechol-O-methyltransferase) and hepatic sulfation; hydrochlorothiazide is not extensively metabolized and is excreted unchanged by the kidney.
Renal (70% unchanged, 20% as metabolites); biliary/fecal (10%)
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
95% bound to albumin and alpha-1-acid glycoprotein
Methyldopa: <10% bound to plasma proteins; hydrochlorothiazide: 40-68% bound to albumin.
0.5-1.0 L/kg; indicates moderate tissue distribution
Methyldopa: Vd 0.2-0.3 L/kg (distributes into tissues, crosses placenta); hydrochlorothiazide: Vd 0.75-1.5 L/kg (extensively distributed, does not cross blood-brain barrier significantly).
Oral: 60-80% (first-pass metabolism reduces from 100%)
Oral bioavailability of methyldopa is approximately 25% (variable, influenced by gut metabolism); hydrochlorothiazide bioavailability is 65-75%.
No dosage adjustment required for renal impairment.
GFR 30-60 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
Severe hepatic impairment (Child-Pugh class C): Use with caution; reduce dose or prolong interval. Child-Pugh class A or B: No adjustment necessary.
Child-Pugh Class B or C: contraindicated; use not recommended.
Not established; safety and efficacy in children have not been studied.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Elderly patients may be more sensitive to hypotensive effects; initiate at lower dose (1 tablet) and titrate carefully.
Start with lowest dose; monitor for hypotension, electrolyte imbalance, and CNS effects; consider reduced initial dose.
None.
None
Reserpine: mental depression, peptic ulcer, ulcerative colitis. Hydralazine: drug-induced lupus erythematosus, peripheral neuritis. Hydrochlorothiazide: electrolyte disturbances, hyperuricemia, acute angle-closure glaucoma, sulfonamide allergy cross-reactivity.
May cause hemolytic anemia, liver disorders, positive Coombs test, sedation, depression, and hypersensitivity reactions. Hydrochlorothiazide may cause electrolyte imbalance, hyperuricemia, photosensitivity, and exacerbation of systemic lupus erythematosus. Use with caution in renal impairment, hepatic disease, and in patients with a history of drug-induced hemolytic anemia.
Reserpine: history of depression, active peptic ulcer, ulcerative colitis, pheochromocytoma, electroconvulsive therapy. Hydralazine: hypersensitivity, coronary artery disease, mitral valvular rheumatic heart disease. Hydrochlorothiazide: anuria, hypersensitivity to sulfonamide-derived drugs.
Active hepatic disease, history of previous methyldopa therapy-associated liver disorders; anuria; hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamide-derived drugs.
Avoid high-potassium foods (bananas, oranges, salt substitutes) due to risk of hyperkalemia with methyldopa. Limit sodium intake for antihypertensive effect. Alcohol may potentiate orthostatic hypotension and sedation.
Food may decrease absorption of methyldopa. Avoid excessive intake of high-potassium foods (e.g., bananas, oranges) unless directed. Hydrochlorothiazide may cause potassium depletion; maintain adequate dietary potassium. Avoid natural licorice as it can worsen hypokalemia.
METATENSIN #4 (combination of hydrochlorothiazide 50 mg and methyldopa 250 mg per tablet) carries teratogenic risks primarily due to hydrochlorothiazide. First trimester: Thiazide diuretics are associated with a small increased risk of neural tube defects and cardiovascular anomalies; however, methyldopa is considered low risk for major malformations. Second trimester: Use may cause fetal electrolyte disturbances and thrombocytopenia. Third trimester: Thiazides can cause neonatal hypotension, hypoglycemia, bone marrow suppression, and volume depletion; methyldopa is associated with neonatal bradycardia and hypotension. Overall risk is considered moderate; alternative antihypertensives are preferred, especially in the first trimester.
First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; possible fetal bradycardia and neonatal hypotension. Hydrochlorothiazide may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
Hydrochlorothiazide is excreted into breast milk in low concentrations (M/P ratio ~0.3), but its use may suppress lactation. Methyldopa is excreted into breast milk with M/P ratio approximately 0.3-0.5; infant exposure is low but may cause bradycardia or sedation. The combination should be used with caution during breastfeeding; monitoring the infant for signs of hypotension, electrolyte imbalance, and sedation is recommended.
Methyldopa is excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Hydrochlorothiazide is excreted in minimal amounts; may suppress lactation. Consider risks versus benefits.
During pregnancy, the pharmacokinetics of methyldopa and hydrochlorothiazide may be altered due to increased plasma volume and renal blood flow. Initial dosing should be based on maternal weight. Methyldopa: Dose may need to be increased in second and third trimesters due to increased clearance; maximum dose 2 g/day. Hydrochlorothiazide: Avoid use in pregnancy due to risks; if absolutely necessary, dose should be minimized. Dose adjustments should be guided by maternal blood pressure response and fetal well-being.
Methyldopa: Pregnancy-induced plasma volume expansion may require dose titration; monitor blood pressure and adjust accordingly. Hydrochlorothiazide: Often avoided in pregnancy due to volume depletion risks; if used, monitor electrolytes and renal function, no pharmacokinetic data necessitate routine dose adjustment.
Metatensin #4 is a combination of thiazide diuretic (hydrochlorothiazide 50 mg) and central alpha-agonist (methyldopa 500 mg). Use with caution in patients with renal impairment; monitor serum creatinine and electrolytes. Avoid abrupt discontinuation (risk of rebound hypertension). May cause positive Coombs test and hemolytic anemia (rare). Dose adjustment required in renal failure (Cr Cl <30 m L/min).
ALDORIL D30 combines methyldopa (central alpha-2 agonist) and hydrochlorothiazide (thiazide diuretic). Monitor for orthostatic hypotension, especially at initiation. Taper not needed for methyldopa but discontinue if fever or liver dysfunction occurs. Interferes with urinary catecholamine measurements (false elevation). Hydrochlorothiazide may cause hyponatremia, hypokalemia, and hyperglycemia; check electrolytes and glucose periodically.
Take exactly as prescribed; do not stop suddenly without consulting your doctor.,May cause dizziness or drowsiness; avoid driving or operating machinery until you know how you react.,Rise slowly from sitting or lying positions to prevent dizziness.,Avoid excessive sweating or dehydration; drink adequate fluids unless fluid-restricted.,Report unusual tiredness, fever, dark urine, yellowing of eyes/skin, or easy bruising/bleeding.,May increase blood sugar; monitor if diabetic.,Avoid alcohol, which can increase dizziness and drowsiness.
Take exactly as prescribed, preferably with food to reduce stomach upset.,Rise slowly from sitting or lying down to prevent dizziness.,This drug may make you drowsy; avoid driving or operating machinery until you know how it affects you.,Report fever, unexplained fatigue, jaundice, or dark urine immediately.,Weigh yourself daily and report rapid weight gain or swelling.,Limit alcohol intake as it can increase side effects.,Do not use salt substitutes containing potassium without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METATENSIN #4 vs ALDORIL D30, answered by our medical review team.
METATENSIN #4 is a Antihypertensive Combination that works by Reserpine depletes catecholamines from central and peripheral nerve terminals by inhibiting vesicular monoamine transporter (VMAT), reducing sympathetic outflow. Hydralazine directly relaxes arteriolar smooth muscle by increasing c GMP levels. Hydrochlorothiazide inhibits sodium-chloride symporter in distal convoluted tubule, reducing plasma volume.. ALDORIL D30 is a Antihypertensive Combination that works by Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METATENSIN #4 and ALDORIL D30 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METATENSIN #4 is: 2 tablets sublingually every 4 hours as needed for angina. Each tablet contains nitroglycerin 0.6 mg.. The standard adult dose of ALDORIL D30 is: Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between METATENSIN #4 and ALDORIL D30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. METATENSIN #4 is classified as Category C. METATENSIN #4 (combination of hydrochlorothiazide 50 mg and methyldopa 250 mg per tablet) carries teratogenic risks primarily due to hydrochlorothiazide. First trimester: Thiazide . ALDORIL D30 is classified as Category C. First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.